This reduced appetite can lead to a decrease in calorie consumption, contributing to weight loss
A multidisciplinary advisory from major nutrition, lifestyle medicine, obesity medicine, and obesity research organizations recommends screening dietary intake, medical conditions, strength, function, physical activity, and other lifestyle factors when initiating GLP-1 therapy
While still relatively new, and not without risks and challenges, GLP1 receptor agonists represent an increasingly powerful tool to effectively manage overweight, obesity, and myriad closely associated chronic medical conditions.
U.S.: The Food and Drug Administration (FDA) is the primary regulatory body, ensuring the safety and efficacy of incretin mimetics like Exenatide, Liraglutide, Dulaglutide, and Semaglutide